Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance. Although home-based working is utilized as much as possible, activities such as source data verification can only be performed onsite.
RPL is now welcoming CRA visits to recommence by adhering to the following exposure prevention policy that is designed to best mitigate risks posed by COVID-19.
I am very pleased with the Project Management of both studies undertaken on behalf of (blank) and any future studies we have to outsource will automatically be contracted to you.
- Anonymous
Many thanks for your time today, most impressed with the quality of the follow up to our enquiry.
- Anonymous
Please know that it has been an absolute pleasure collaborating with you and that I am most appreciative of the key contributions RPL has made to this project thus far. I hope I have the opportunity to work with RPL again in the very near future.
- Anonymous
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing
Read more ›Richmond Pharmacology update on SARS-CoV-2 infection control and management of clinical trials
Read more ›Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are
Read more ›Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON
View event ›
+44 (0) 20 7042 5800
